Busey Trust CO raised its position in Johnson & Johnson (NYSE:JNJ) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 156,656 shares of the company’s stock after buying an additional 1,188 shares during the period. Johnson & Johnson makes up approximately 2.4% of Busey Trust CO’s investment portfolio, making the stock its 7th largest position. Busey Trust CO’s holdings in Johnson & Johnson were worth $19,512,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of JNJ. Empirical Finance LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $144,000. Highland Capital Management LP purchased a new position in Johnson & Johnson during the fourth quarter valued at $461,000. Massmutual Trust Co. FSB ADV purchased a new position in Johnson & Johnson during the fourth quarter valued at $15,427,000. Fiduciary Financial Services of The Southwest Inc. TX boosted its stake in Johnson & Johnson by 4.1% in the fourth quarter. Fiduciary Financial Services of The Southwest Inc. TX now owns 14,803 shares of the company’s stock valued at $1,705,000 after buying an additional 581 shares in the last quarter. Finally, Gyroscope Capital Management Group LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $691,000. Institutional investors own 66.10% of the company’s stock.
Johnson & Johnson (NYSE JNJ) opened at 132.63 on Friday. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The firm’s 50-day moving average price is $132.88 and its 200 day moving average price is $127.04. The firm has a market cap of $355.98 billion, a PE ratio of 22.44 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the previous year, the business earned $1.74 EPS. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 56.76%.
TRADEMARK VIOLATION NOTICE: This story was first posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/johnson-johnson-jnj-shares-bought-by-busey-trust-co-updated-updated.html.
Several equities research analysts recently commented on the company. Jefferies Group LLC set a $145.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday. J P Morgan Chase & Co raised their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday. Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $134.12.
In related news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.